Gossamer Bio Past Earnings Performance
Past criteria checks 0/6
Gossamer Bio's earnings have been declining at an average annual rate of -4.5%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
-4.5%
Earnings growth rate
40.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -286.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Gossamer Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -180 | 38 | 135 |
| 30 Sep 23 | 0 | -187 | 42 | 147 |
| 30 Jun 23 | 0 | -207 | 44 | 160 |
| 31 Mar 23 | 0 | -221 | 46 | 166 |
| 31 Dec 22 | 0 | -229 | 48 | 171 |
| 30 Sep 22 | 0 | -230 | 43 | 170 |
| 30 Jun 22 | 0 | -231 | 44 | 169 |
| 31 Mar 22 | 0 | -234 | 44 | 171 |
| 31 Dec 21 | 0 | -234 | 46 | 170 |
| 30 Sep 21 | 0 | -242 | 51 | 168 |
| 30 Jun 21 | 0 | -240 | 50 | 167 |
| 31 Mar 21 | 0 | -247 | 50 | 161 |
| 31 Dec 20 | 0 | -243 | 50 | 161 |
| 30 Sep 20 | 0 | -233 | 45 | 165 |
| 30 Jun 20 | 0 | -224 | 44 | 163 |
| 31 Mar 20 | 0 | -202 | 42 | 160 |
| 31 Dec 19 | 0 | -180 | 39 | 143 |
| 30 Sep 19 | 0 | -164 | 41 | 127 |
| 30 Jun 19 | 0 | -165 | 55 | 105 |
| 31 Mar 19 | 0 | -154 | 49 | 78 |
| 31 Dec 18 | 0 | -147 | 44 | 55 |
| 30 Sep 18 | 0 | -115 | 30 | 30 |
| 30 Jun 18 | 0 | -66 | 7 | 11 |
| 31 Mar 18 | 0 | -33 | 3 | 4 |
| 31 Dec 17 | 0 | -7 | 0 | 1 |
Quality Earnings: 4GB is currently unprofitable.
Growing Profit Margin: 4GB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4GB is unprofitable, and losses have increased over the past 5 years at a rate of 4.5% per year.
Accelerating Growth: Unable to compare 4GB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4GB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 4GB has a negative Return on Equity (-286.47%), as it is currently unprofitable.